REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does REVIVA PHARMACEUTICALS HOLDINGS, INC. Do?
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California. REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Laxminarayan Bhat and employs approximately 5 people. With a market capitalization of $10M, RVPH is one of the notable companies in the Healthcare sector.
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) Stock Rating — Reduce (April 2026)
As of April 2026, REVIVA PHARMACEUTICALS HOLDINGS, INC. receives a Reduce rating with a composite score of 35.0/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.RVPH ranks #3,723 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, REVIVA PHARMACEUTICALS HOLDINGS, INC. ranks #622 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
RVPH Stock Price and 52-Week Range
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) currently trades at $0.78. The stock lost $0.06 (7.7%) in the most recent trading session. The 52-week high for RVPH is $4.84, which means the stock is currently trading -83.9% from its annual peak. The 52-week low is $0.20, putting the stock 290.8% above its annual trough. Recent trading volume was 484K shares, suggesting relatively thin trading activity.
Is RVPH Overvalued or Undervalued? — Valuation Analysis
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) carries a value factor score of 9/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.16x, versus the sector average of 2.75x.
At current multiples, REVIVA PHARMACEUTICALS HOLDINGS, INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.
REVIVA PHARMACEUTICALS HOLDINGS, INC. Profitability — ROE, Margins, and Quality Score
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) earns a quality factor score of 10/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -287.5%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -156.1% versus the sector average of -33.1%.
Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
RVPH Debt, Balance Sheet, and Financial Health
REVIVA PHARMACEUTICALS HOLDINGS, INC. has a debt-to-equity ratio of 84.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 2.08x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $13M.
RVPH has a beta of -1.16, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for REVIVA PHARMACEUTICALS HOLDINGS, INC. is 28/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.
REVIVA PHARMACEUTICALS HOLDINGS, INC. Revenue and Earnings History — Quarterly Trend
In TTM 2026, REVIVA PHARMACEUTICALS HOLDINGS, INC. reported revenue of $0 and earnings per share (EPS) of $-5.48. Net income for the quarter was $-25M. Operating income came in at $-25M.
In FY 2025, REVIVA PHARMACEUTICALS HOLDINGS, INC. reported revenue of $0 and earnings per share (EPS) of $-5.48. Net income for the quarter was $-20M. Operating income came in at $-20M.
In Q3 2025, REVIVA PHARMACEUTICALS HOLDINGS, INC. reported revenue of $0 and earnings per share (EPS) of $-0.06. Net income for the quarter was $-4M. Operating income came in at $-4M.
In Q2 2025, REVIVA PHARMACEUTICALS HOLDINGS, INC. reported revenue of $0 and earnings per share (EPS) of $-0.12. Net income for the quarter was $-6M. Operating income came in at $-6M.
Over the past 8 quarters, REVIVA PHARMACEUTICALS HOLDINGS, INC. has experienced revenue contraction from $0 to $0. Investors analyzing RVPH stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
RVPH Dividend Yield and Income Analysis
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
RVPH Momentum and Technical Analysis Profile
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) has a momentum factor score of 75/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 69/100 reflects moderate short selling activity.
RVPH vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) ranks #622 out of 838 stocks based on the Blank Capital composite score. This places RVPH in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing RVPH against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full RVPH vs S&P 500 (SPY) comparison to assess how REVIVA PHARMACEUTICALS HOLDINGS, INC. stacks up against the broader market across all factor dimensions.
RVPH Next Earnings Date
No upcoming earnings date has been announced for REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy RVPH? — Investment Thesis Summary
The quantitative profile for REVIVA PHARMACEUTICALS HOLDINGS, INC. suggests caution. The quality score of 10/100 flags below-average profitability. The value score of 9/100 indicates premium valuation. Price momentum is positive at 75/100, suggesting the trend favors buyers. High volatility (stability score 28/100) increases portfolio risk.
In summary, REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) earns a Reduce rating with a composite score of 35.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on RVPH stock.
Related Resources for RVPH Investors
Explore more research and tools: RVPH vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare RVPH head-to-head with peers: RVPH vs AZN, RVPH vs SLGL, RVPH vs VMD.